{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:49Z","timestamp":1785387589032,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opsoclonus\u2013myoclonus\u2013ataxia syndrome (OMAS) is a rare hyperkinetic movement disorder characterized by opsoclonus, generalized myoclonus, and cerebellar ataxia. In adults, OMAS is most often reported in paraneoplastic or postinfectious settings, whereas autoimmune etiologies are less common.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 21-year-old woman with a 7-month history of SLE developed a 3-week subacute OMAS phenotype with opsoclonus, generalized myoclonus, and gait\/limb ataxia, leading to loss of independent ambulation. CSF, microbiological testing, and brain MRI were unremarkable, and initial malignancy screening was negative. Severe lupus activity was documented (SLEDAI-2\u202fK 27). She received methylprednisolone pulses, plasmapheresis, and rituximab, with progressive neurological recovery and a decrease in lupus activity to SLEDAI-2\u202fK 4. At discharge, she ambulated independently with mild residual gait ataxia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case expands the spectrum of neuropsychiatric SLE by illustrating OMAS as a predominantly motor phenotype. A structured evaluation to exclude structural, infectious, and malignant etiologies is essential, and early escalation of immunotherapy may be associated with substantial neurological recovery when OMAS occurs in the context of severe lupus activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1816940","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:22:13Z","timestamp":1785385333000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A rare motor storm in lupus: opsoclonus-myoclonus-ataxia syndrome as an atypical presentation of severe systemic lupus erythematosus"],"prefix":"10.3389","volume":"13","author":[{"given":"Marco Vinicio","family":"Culqui-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Facultad de Salud y Bienestar, Pontificia Universidad Cat\u00f3lica del Ecuador","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Felipe Romero","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Facultad de Salud y Bienestar, Pontificia Universidad Cat\u00f3lica del Ecuador","place":["Quito, Ecuador"]},{"name":"Servicio de Neurolog\u00eda, Hospital de Especialidades Eugenio Espejo","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Roc\u00edo","family":"Di Capua Sacoto","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital de Especialidades Eugenio Espejo","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ortiz-Prado","sequence":"additional","affiliation":[{"name":"One Health Research Group, Universidad de Las Americas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Izquierdo-Condoy","sequence":"additional","affiliation":[{"name":"One Health Research Group, Universidad de Las Americas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/1744666X.2019.1564040","article-title":"Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus","volume":"15","author":"de Amorim","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41584-024-01163-z","article-title":"Recent advances in the diagnosis and management of neuropsychiatric lupus","volume":"20","author":"Legge","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00415-018-9138-7","article-title":"Update on opsoclonus\u2013myoclonus syndrome in adults","volume":"266","author":"Oh","year":"2019","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/CON.0000000000001455","article-title":"Autoimmune Movement Disorders","volume":"30","author":"Balint","year":"2024","journal-title":"Contin Lifelong Learn Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.17116\/jnevro2024124121165","article-title":"Paraneoplastic opsoclonus-myoclonus syndrome","volume":"124","author":"Fedoseeva","year":"2024","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e000414","DOI":"10.1136\/bmjno-2023-000414","article-title":"Opsoclonus myoclonus ataxia syndrome, ovarian teratoma and anti-NMDAR antibody: an \u20ac unresolved\u2019 mystery","volume":"5","author":"Miraclin","year":"2023","journal-title":"BMJ Neurol Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13760-022-02029-5","article-title":"Opsoclonus myoclonus ataxia syndrome following COVID-19 infection","volume":"123","author":"Ismail","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1002\/mdc3.70117","article-title":"Opsoclonus-myoclonus: not always paraneoplastic","volume":"12","author":"Lustosa Cabral Gomez","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/B978-0-444-64189-2.00021-4","article-title":"Immune-mediated ataxias","volume":"155","author":"Joubert","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jns.2017.12.035","article-title":"Autoimmune and paraneoplastic movement disorders: an update","volume":"385","author":"Baizabal-Carvallo","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/WCO.0b013e328347b307","article-title":"Movement disorders in paraneoplastic and autoimmune disease","volume":"24","author":"Panzer","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"998328","DOI":"10.3389\/fcell.2022.998328","article-title":"Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review","volume":"10","author":"Liu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/archneurol.2012.1173","article-title":"Adult-onset opsoclonus-myoclonus syndrome","volume":"69","author":"Klaas","year":"2012","journal-title":"Arch Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jns.2019.10.1305","article-title":"Adult onset opsoclonus-myoclonus-ataxia syndrome, clinical features and diagnostic findings","volume":"405","author":"Daoud","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5152\/eurjrheum.2023.22095","article-title":"Neuropsychiatric manifestations in systemic lupus erythematosus patients at a tertiary hospital in Peru","volume":"10","author":"C-H","year":"2023","journal-title":"Eur J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1111769","DOI":"10.3389\/fneur.2023.1111769","article-title":"The conundrum of neuropsychiatric systemic lupus erythematosus: current and novel approaches to diagnosis","volume":"14","author":"Emerson","year":"2023","journal-title":"Front Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2022-0024","DOI":"10.5935\/0004-2749.2022-0024","article-title":"Adult-onset idiopathic opsoclonus-myoclonus syndrome","volume":"87","author":"Zhang","year":"2023","journal-title":"Arq Bras Oftalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1097\/MS9.0000000000002361","article-title":"Central neurological manifestations in a sample of Syrian patients with systemic lupus erythematosus: cross-sectional study","volume":"86","author":"Kudsi","year":"2024","journal-title":"Ann Med Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/rheumatology\/kead297","article-title":"Neuropsychiatric lupus in late- and early-onset systemic lupus erythematosus patients: a systematic review and meta-analysis","volume":"63","author":"Pamuk","year":"2024","journal-title":"Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11910-019-1012-1","article-title":"Neurological complications in patients with systemic lupus erythematosus","volume":"19","author":"Shaban","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.55563\/clinexprheumatol\/jrz47c","article-title":"Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation","volume":"40","author":"Tani","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules29040747","article-title":"Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment","volume":"4","author":"Justiz-Vaillant","year":"2024","journal-title":"Molecules"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2024-225617","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1816940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:22:14Z","timestamp":1785385334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1816940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1816940"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1816940","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1816940"}}